Abstract: A crosslinkable stabilized composition for a nonwoven substrate includes an aqueous dispersion of vinyl acetate-ethylene copolymers, a polyvinyl alcohol dispersion stabilizer, and a copolymer comprising maleic anhydride units or a copolymer comprising maleic acid units. The composition exhibits a free formaldehyde content of 5 ppm or less.

Abstract: An antimicrobial nonwoven wet wipe includes i) a fibrous nonwoven substrate bonded with a crosslinkable VAE dispersion stabilized with one or more cationic vinyl alcohol-N-vinyl amine copolymer protective colloids, and ii) an aqueous lotion containing a cationic disinfectants absorbed in the nonwoven substrate. No anionic surfactants are present. The antimicrobial nonwoven wet wipes are produced by a) applying an aqueous composition including a crosslinkable VAE dispersion stabilized with one or more cationic vinyl alcohol-N-vinyl amine copolymers to a nonwoven substrate; b) drying; and c) applying an aqueous composition to the product of step b). At least one of the first and second aqueous com-positions includes a cationic disinfectant.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

Abstract: The present invention relates to a combination therapy of 2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N?-(2,2,3,3,3-pentafluoro-propyl)-malonamide, or a pharmaceutically-acceptable salt thereof, and bevacizumab for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example a brain tumor.

Abstract: A radiopaque nitinol medical device such as a stent for use with or implantation in a body lumen is disclosed. The stent is made from a superelastic alloy such as nickel-titanium or nitinol, and includes a ternary element selected from the group of chemical elements consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium. The added ternary element improves the radiopacity of the nitinol stent comparable to that of a stainless steel stent of the same and strut pattern coated with a thin layer of gold. The nitinol stent has improved radioplacity yet retains its superelastic and shape memory behavior and further maintains a thin strut/wall thickness for high flexibility.

Abstract: A stent and a delivery system for implanting the stent in a body lumen is disclosed. The stent is made from a superelastic alloy such as nickel-titanium or nitinol, and includes a ternary element in order to minimize the stress hysteresis of the superelastic material. The stress hysteresis is defined by the difference between the loading plateau stress and the unloading plateau stress of the superelastic material. The resulting delivery system has a small profile and includes a sheath covering the stent that has a thin wall. A guide wire core can also be made from the small stress hysteresis superelastic material.

Abstract: An elongated core member and an expandable frame for an embolic filtering device used to capture embolic debris in a body lumen. The expandable frame also includes a filtering element. A nickel-titanium alloy is used to form the frame, the elongated core member, or both the frame and the elongated core member. The nickel-titanium alloy includes at least one ternary element, such as iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium, so that the frame and/or elongated core member is also radiopaque.

Abstract: A waterborne hydrophobic barrier coating formulation comprising a blend of a vinyl acetate-ethylene (VAE) polymer emulsion and a paraffin wax emulsion, wherein a dried coating of the blend on a substrate, such as a nonwoven web, an absorbent pad, or a textile, and dried, has a hydrostatic head barrier sufficient to prevent passage of fluids but allow passage of water vapor through it. A multi-layer material comprising at least one layer of a nonwoven web, an absorbent pad, or a textile, and at least one layer of a blend of a VAE polymer emulsion and paraffin wax emulsion.

Abstract: A nickel-titanium alloy having a large, superelastic operating temperature window or range. The nickel-titanium alloy includes at least an additional element such as platinum, palladium, manganese, boron, aluminum, tungsten, and/or zirconium. When processed through heat treat and area reduction steps, the resultant alloy exhibits a wide superelastic temperature operating window if the characteristics of the alloy when plotted on a temperature versus stress curve can be expressed as UP=(0.66 ksi/° C.)(T)+?0, with R2?0.98, wherein ?0 is the upper plateau stress of the alloy at about 0° C., R2 is the coefficient of determination, and UP is the upper plateau stress of the alloy.

Abstract: The present invention relates to a serine threonine kinase. The invention also relates to nucleic acids encoding the kinase, vectors, host cells, antibodies and recombinant methods for producing the h2520-59 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for h2520-59 and related products.

Abstract: This invention is directed to an improvement in binders particularly suited for use in preparing nonwoven products and to the nonwoven products. The improved binders comprise a blend of a vinyl chloride (VCl) polymer emulsion and a self crosslinkable vinyl acetate-ethylene-N-methylolacrylamide (VAE-NMA) polymer emulsion. The blend of the VCl polymer emulsion and the VAE-NMA polymer emulsion can be applied to cellulose and cellulose/synthetic nonwoven substrates and cured in the absence of an acid catalyst to provide a self-sustaining web having excellent wet strength performance.

Abstract: This invention is directed to an improvement in binders particularly suited for use in preparing nonwoven products and to the nonwoven products. The improved binders comprise a blend of emulsion polymerized ethylene-vinyl chloride (EVCl) polymer and an emulsion polymerized self crosslinkable vinyl acetate-ethylene-N-methylolacrylamide (VAE-NMA) polymer. The blends of the EVCl polymer emulsion and the VAE-NMA polymer emulsion can be applied to cellulose and cellulose/synthetic nonwoven substrates and cured in the absence of an acid catalyst to provide a self-sustaining web having excellent wet strength performance. The blends of EVCl and VAE-NMA polymers do not require an acid catalyst to facilitate cure.